Fair Value Measurements - Narrative (Details)		1 Months Ended				3 Months Ended			12 Months Ended
	Aug. 04, 2021 shares	Aug. 31, 2023 shares	Oct. 31, 2022 USD ($)	Aug. 31, 2022 shares	Aug. 31, 2021 sale shares	Sep. 30, 2023 shares	Sep. 30, 2022 shares	Sep. 30, 2021 shares	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 01, 2025	May 31, 2021 USD ($)	Jan. 31, 2018 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Purchase of marketable securities									$ 588,733,000	$ 99,706,000	$ 50,292,000
Available-for-sale, unrealized loss									700,000	500,000
Fair value transfers in or out of Level 1, Level 2 or Level 3									0	0
Proceeds from issuance Royalty Financing Agreement									0	150,000,000	$ 0
Convertible notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible senior notes														$ 309,100,000
Unamortized debt issuance costs									$ 11,091,000	14,379,000
0.75% convertible senior notes due 2028 | Convertible notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate (as a percent)									0.75%
Convertible senior notes													$ 371,600,000
Unamortized debt issuance costs									$ 10,000,000				15,700,000
Original Term Loan balance													575,000,000
1.75% convertible senior note due 2025 | Convertible notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate (as a percent)									1.75%
Convertible senior notes													$ 203,400,000
Unamortized debt issuance costs									$ 1,100,000					14,200,000
Original Term Loan balance														$ 450,000,000
Royalty Agreements
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty maximum			1.8
Royalty Agreements | Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty maximum			1.9
Royalty Agreements | ARIKAYCE Global Net Sales
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty percentage			400.00%
Royalty Agreements | ARIKAYCE Global Net Sales | Subsequent Event
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty percentage												450.00%
Royalty Agreements | Brensocatib Global Net Sales | Subsequent Event
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Royalty percentage												75.00%
Royalty Agreements | Secured Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds from issuance Royalty Financing Agreement			$ 150,000,000
Revenue interest payment			150,000,000
Original Term Loan balance			150,000,000
Lenders fees and deal expenses			3,600,000
Proceeds from royalty financing agreement, net			$ 146,400,000
Development and regulatory milestones
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Weighted-average probability of reaching milestone, percentage									42.00%
Accrued Liabilities, Current
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred consideration									$ 5,700,000
Motus Biosciences, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued in acquisition (in shares) | shares	2,889,367	177,203		171,427	171,427	177,203	171,427	2,889,367
Shares issued upon milestone achievements (in shares) | shares	5,348,572				5,348,572
Motus Biosciences, Inc. | Development and regulatory milestones
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Proceeds of sale of priority review voucher obligated to pay to equity holders, percentage					50.00%
Potential payout, average sales prices for publicly disclosed sales, percentage					50.00%
Number of publicly disclosed sales used to determine average sales price owed to equity holders | sale					3
Motus Biosciences, Inc. | First anniversary of closing date
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued in acquisition (in shares) | shares	184,433				184,433
Motus Biosciences, Inc. | Second anniversary of closing date
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued in acquisition (in shares) | shares	184,433				184,433
Motus Biosciences, Inc. | Third anniversary of closing date
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued in acquisition (in shares) | shares	184,433				184,433
AlgaeneX, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued upon milestone achievements (in shares) | shares	368,867
Carrying Value | Recurring basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities									298,100,000	74,200,000
Deferred consideration									5,700,000	7,400,000
Carrying Value | Recurring basis | 0.75% convertible senior notes due 2028 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible senior notes									565,000,000
Carrying Value | Recurring basis | 1.75% convertible senior note due 2025 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible senior notes									223,900,000
Fair Value | Recurring basis | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities									0	0
Deferred consideration									5,700,000	$ 7,400,000
Fair Value | Recurring basis | 0.75% convertible senior notes due 2028 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible senior notes									665,500,000
Fair Value | Recurring basis | 1.75% convertible senior note due 2025 | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible senior notes									$ 240,200,000